Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment
Cancer Chemotherapy and Pharmacology · 2025
DOI: 10.1007/s00280-025-04797-2 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Yiming Cheng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Hauptthemen laut MEDLINE: Triazines, Aminopyridines, Liver Diseases, Antineoplastic Agents. Die Arbeit nennt 18 Literaturangaben. Gefördert von: Bristol-Myers Squibb.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA.
- Hematology Global Drug Development, Bristol Myers Squibb, Giralda Farms, NJ, USA.
- WorldWide Patient Safety, Bristol Myers Squibb, San Diego, CA, USA.
- Hematology Clinical Science, Bristol Myers Squibb, Giralda Farms, NJ, USA.
- Early Clinical Development Hematology and Cell Therapy, Giralda Farms, NJ, USA.
- Clinical Pharmacology, Pharmacometrics & Bioanalysis, Bristol Myers Squibb, Princeton, NJ, USA. Yan.Li@bms.com.
Förderung
- Bristol-Myers Squibb
Zitieren
APA
Cheng, Y., Chen, J., Vigil, C., Khanzadeh, S., Rampersad, A., Prebet, T., & Li, Y. (2025). Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04797-2
Vancouver
Cheng Y, Chen J, Vigil C, Khanzadeh S, Rampersad A, Prebet T, et al. Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04797-2
BibTeX
@article{Cheng2025,
author = {Cheng, Yiming and Chen, Jian and Vigil, Carlos and Khanzadeh, Shahram and Rampersad, Anita and Prebet, Thomas and Li, Yan},
title = {Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2025},
doi = {10.1007/s00280-025-04797-2}
}
EUVIMED